AR083475A1 - METABOTROPIC GLUTAMATE RECEIVERS MODULATORS - Google Patents
METABOTROPIC GLUTAMATE RECEIVERS MODULATORSInfo
- Publication number
- AR083475A1 AR083475A1 ARP110103856A ARP110103856A AR083475A1 AR 083475 A1 AR083475 A1 AR 083475A1 AR P110103856 A ARP110103856 A AR P110103856A AR P110103856 A ARP110103856 A AR P110103856A AR 083475 A1 AR083475 A1 AR 083475A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- amino
- represents hydrogen
- fluorine
- Prior art date
Links
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 150000002431 hydrogen Chemical group 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 10
- 239000011737 fluorine Chemical group 0.000 abstract 10
- 229910052731 fluorine Inorganic materials 0.000 abstract 10
- 229910052757 nitrogen Chemical group 0.000 abstract 10
- -1 amino, hydroxy Chemical group 0.000 abstract 9
- 229910052760 oxygen Inorganic materials 0.000 abstract 9
- 229910052717 sulfur Inorganic materials 0.000 abstract 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 8
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 239000001301 oxygen Chemical group 0.000 abstract 8
- 239000011593 sulfur Substances 0.000 abstract 8
- 125000002252 acyl group Chemical group 0.000 abstract 7
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 7
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 7
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 150000001721 carbon Chemical group 0.000 abstract 5
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Proceso para la preparación de dichos compuestos. Los compuestos son moduladores de mGluR5 y por ello son de utilidad para el control y la prevención de trastornos neurológicos agudos y/o crónicos.Reivindicación 1: Un compuesto caracterizado porque se selecciona entre aquellos de la fórmula (1) donde R1 representa arilo, heteroarilo, cicloalquilo C3-12, cicloalquenilo C5-12, o heterociclilo; R2 representa hidrógeno, flúor, o alquilo C1-6; R3 representa hidrógeno, flúor, o alquilo C1-6; o R2 y R3 junto con el átomo de carbono al cual se encuentran unidos forman un anillo de entre 3 y 7 miembros que puede ser saturado o insaturado, donde el anillo opcionalmente puede contener uno o dos heteroátomos seleccionados entre azufre, oxígeno, y nitrógeno y donde el anillo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, amino, hidroxi, ciano, acilo, alquilamino C1-6, di-(alquil C1-6)amino, alquilcarbonilamino C1-6, y oxo; W representa CH2, -CR4R5CH2-, O, S, -CR6R7O-, NR8, o -CR9R10NR11-; Y representa CR12R13, o NR14; R4 representa hidrógeno, flúor, o alquilo C1-6; R5 representa hidrógeno, flúor, o alquilo C1-6; o R4 y R5 junto con el átomo de carbono al cual se encuentran unidos forman un anillo de entre 3 y 7 miembros que puede ser saturado o insaturado, donde el anillo opcionalmente puede contener uno o dos heteroátomos seleccionados entre azufre, oxígeno, y nitrógeno y donde el anillo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, amino, hidroxi, ciano, acilo, alquilamino C1-6, di-(alquil C1-6)amino, alquilcarbonilamino C1-6, y oxo; R6 representa hidrógeno, flúor, o alquilo C1-6; R7 representa hidrógeno, flúor, o alquilo C1-6; o R6 y R7 junto con el átomo de carbono al cual se encuentran unidos forman un anillo de entre 3 y 7 miembros que puede ser saturado o insaturado, donde el anillo opcionalmente puede contener uno o dos heteroátomos seleccionados entre azufre, oxígeno, y nitrógeno y donde el anillo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, amino, hidroxi, ciano, acilo, alquilamino C1-6, di-(alquil C1-6)amino, alquilcarbonilamino C1-6, y oxo; R8 representa hidrógeno, alquilo C1-6, o acilo; R9 representa hidrógeno, flúor, o alquilo C1-6; R10 representa hidrógeno, flúor, o alquilo C1-6; o R9 y R10 junto con el átomo de carbono al cual se encuentran unidos forman un anillo de entre 3 y 7 miembros que puede ser saturado o insaturado, donde el anillo opcionalmente puede contener uno o dos heteroátomos seleccionados entre azufre, oxígeno, y nitrógeno y donde el anillo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, amino, hidroxi, ciano, acilo, alquilamino C1-6, di-(alquil C1-6)amino, alquilcarbonilamino C1-6, y oxo; R11 representa hidrógeno, alquilo C1-6, o acilo; R12 representa hidrógeno, flúor, alquilo C1-6, amino, alquilamino C1-6, di-(alquil C1-6)amino, acilamino, o heterociclilo; R13 representa hidrógeno, flúor, o alquilo C1-6; o R12 y R13 junto con el átomo de carbono al cual se encuentran unidos forman un anillo de entre 3 y 7 miembros que puede ser saturado o insaturado, donde el anillo opcionalmente puede contener uno o dos heteroátomos seleccionados entre azufre, oxígeno, y nitrógeno y donde el anillo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre halógeno, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, amino, hidroxi, ciano, acilo, alquilamino C1-6, di-(alquil C1-6)amino, alquilcarbonilamino C1-6, y oxo; y R14 representa hidrógeno, alquilo C1-6, arilo, o heteroarilo; donde el término “arilo” significa fenilo o naftilo, donde el grupo fenilo o naftilo está opcionalmente sustituido con uno o más sustituyentes, que pueden ser iguales o diferentes, seleccionados en forma independiente entre halógeno, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, alquilo C1-6, hidroxialquilo C1-6, alquenilo C2-6, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, amino, hidroxi, nitro, ciano, formilo, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, alquilcarboniloxi C1-6, alquilcarboniloxi C1-6-alquilo C1-6, alquilamino C1-6, di-(alquil C1-6)amino, cicloalquilamino C3-12, alquilcarbonilamino C1-6, fenilcarbonilamino, aminocarbonilo, N-alquilaminocarbonilo C1-6, di-N,N-alquilaminocarbonilo C1-6, pirrolidinilo, piperidinilo, morfolinilo, piperazinilo, cicloalquilo C3-12, piridinilo, y alquilendioxi C1-6; el término “heteroarilo” significa un anillo aromático de 5 ó 6 miembros que contiene entre uno y cuatro heteroátomos seleccionados entre oxígeno, azufre y nitrógeno, o un grupo bicíclico que comprende un anillo de 5 ó 6 miembros que contiene entre uno y cuatro heteroátomos seleccionados entre oxígeno, azufre y nitrógeno fusionado con un anillo benceno o un anillo de 5 ó 6 miembros que contiene entre uno y cuatro heteroátomos seleccionados entre oxígeno, azufre y nitrógeno, donde el grupo heteroarilo puede estar opcionalmente sustituido con uno o más sustituyentes, que pueden ser iguales o diferentes, seleccionados en forma independiente entre halógeno, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, alquilo C1-6, hidroxialquilo C1-6, alquenilo C2-6, alcoxi C1-6, amino, hidroxi, nitro, ciano, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, alcoxicarboniloxi C1-6, alquilamino C1-6, y di-(alquil C1-6)amino, cicloalquilamino C3-12, alquilcarbonilamino C1-6, aminocarbonilo, N-alquilaminocarbonilo C1-6, di-N,N-alquilaminocarbonilo C1-6, pirrolidinilo, piperidinilo, morfolinilo, cicloalquilo C3-12, alquilendioxi C1-6, arilo, y piridinilo; e isómeros ópticos, prodrogas, sales farmacéuticamente aceptables, hidratos, solvatos y polimorfos del mismo.Process for the preparation of said compounds. The compounds are modulators of mGluR5 and are therefore useful for the control and prevention of acute and / or chronic neurological disorders. Claim 1: A compound characterized in that it is selected from those of the formula (1) where R1 represents aryl, heteroaryl , C3-12 cycloalkyl, C5-12 cycloalkenyl, or heterocyclyl; R2 represents hydrogen, fluorine, or C1-6 alkyl; R3 represents hydrogen, fluorine, or C1-6 alkyl; or R2 and R3 together with the carbon atom to which they are attached form a ring of between 3 and 7 members that can be saturated or unsaturated, where the ring can optionally contain one or two heteroatoms selected from sulfur, oxygen, and nitrogen and where the ring may be optionally substituted with one or more substituents selected from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, C1-6 alkoxy, amino, hydroxy, cyano, acyl, C1-6 alkylamino, di- ( C1-6 alkyl) amino, C1-6 alkylcarbonylamino, and oxo; W represents CH2, -CR4R5CH2-, O, S, -CR6R7O-, NR8, or -CR9R10NR11-; Y represents CR12R13, or NR14; R4 represents hydrogen, fluorine, or C1-6 alkyl; R5 represents hydrogen, fluorine, or C1-6 alkyl; or R4 and R5 together with the carbon atom to which they are attached form a ring of between 3 and 7 members that can be saturated or unsaturated, where the ring can optionally contain one or two heteroatoms selected from sulfur, oxygen, and nitrogen and where the ring may be optionally substituted with one or more substituents selected from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, C1-6 alkoxy, amino, hydroxy, cyano, acyl, C1-6 alkylamino, di- ( C1-6 alkyl) amino, C1-6 alkylcarbonylamino, and oxo; R6 represents hydrogen, fluorine, or C1-6 alkyl; R7 represents hydrogen, fluorine, or C1-6 alkyl; or R6 and R7 together with the carbon atom to which they are attached form a ring of between 3 and 7 members that can be saturated or unsaturated, where the ring can optionally contain one or two heteroatoms selected from sulfur, oxygen, and nitrogen and where the ring may be optionally substituted with one or more substituents selected from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, C1-6 alkoxy, amino, hydroxy, cyano, acyl, C1-6 alkylamino, di- ( C1-6 alkyl) amino, C1-6 alkylcarbonylamino, and oxo; R 8 represents hydrogen, C 1-6 alkyl, or acyl; R9 represents hydrogen, fluorine, or C1-6 alkyl; R10 represents hydrogen, fluorine, or C1-6 alkyl; or R9 and R10 together with the carbon atom to which they are attached form a ring of between 3 and 7 members that can be saturated or unsaturated, where the ring can optionally contain one or two heteroatoms selected from sulfur, oxygen, and nitrogen and where the ring may be optionally substituted with one or more substituents selected from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, C1-6 alkoxy, amino, hydroxy, cyano, acyl, C1-6 alkylamino, di- ( C1-6 alkyl) amino, C1-6 alkylcarbonylamino, and oxo; R 11 represents hydrogen, C 1-6 alkyl, or acyl; R 12 represents hydrogen, fluorine, C 1-6 alkyl, amino, C 1-6 alkylamino, di- (C 1-6 alkyl) amino, acylamino, or heterocyclyl; R13 represents hydrogen, fluorine, or C1-6 alkyl; or R12 and R13 together with the carbon atom to which they are attached form a ring of between 3 and 7 members that can be saturated or unsaturated, where the ring can optionally contain one or two heteroatoms selected from sulfur, oxygen, and nitrogen and where the ring may be optionally substituted with one or more substituents selected from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, C1-6 alkoxy, amino, hydroxy, cyano, acyl, C1-6 alkylamino, di- ( C1-6 alkyl) amino, C1-6 alkylcarbonylamino, and oxo; and R14 represents hydrogen, C1-6 alkyl, aryl, or heteroaryl; wherein the term "aryl" means phenyl or naphthyl, where the phenyl or naphthyl group is optionally substituted with one or more substituents, which may be the same or different, independently selected from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C1 alkyl -6, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, amino, hydroxy, nitro, cyano, formyl, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonyloxy -6, C 1-6 alkylcarbonyloxy-C 1-6 alkyl, C 1-6 alkylamino, di- (C 1-6 alkyl) amino, C 3-12 cycloalkylamino, C 1-6 alkylcarbonylamino, phenylcarbonylamino, aminocarbonyl, N- C 1-6 alkylaminocarbonyl, di -N, N- C 1-6 alkylaminocarbonyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, C 3-12 cycloalkyl, pyridinyl, and C 1-6 alkylenedioxy; the term "heteroaryl" means a 5- or 6-membered aromatic ring containing between one and four heteroatoms selected from oxygen, sulfur and nitrogen, or a bicyclic group comprising a 5- or 6-membered ring containing between one and four selected heteroatoms. between oxygen, sulfur and nitrogen fused with a benzene ring or a 5- or 6-membered ring containing between one and four heteroatoms selected from oxygen, sulfur and nitrogen, where the heteroaryl group may be optionally substituted with one or more substituents, which may be the same or different, independently selected from halogen, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, hydroxy C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, amino, hydroxy, nitro, cyano, C1 alkylcarbonyl -6, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonyloxy, C1-6 alkylamino, and di- (C1-6 alkyl) amino, C3-12 cycloalkylamino, C1-6 alkylcarbonylamino , aminocarbonyl, N- C 1-6 alkylaminocarbonyl, di-N, N-C 1-6 alkylaminocarbonyl, pyrrolidinyl, piperidinyl, morpholinyl, C 3-12 cycloalkyl, C 1-6 alkylenedioxy, aryl, and pyridinyl; and optical isomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates and polymorphs thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45529010P | 2010-10-18 | 2010-10-18 | |
| EP10187954 | 2010-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083475A1 true AR083475A1 (en) | 2013-02-27 |
Family
ID=43618690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103856A AR083475A1 (en) | 2010-10-18 | 2011-10-18 | METABOTROPIC GLUTAMATE RECEIVERS MODULATORS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR083475A1 (en) |
| WO (1) | WO2012052451A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130274294A1 (en) * | 2010-12-20 | 2013-10-17 | David Carcache | 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters |
| WO2012151139A1 (en) * | 2011-05-03 | 2012-11-08 | Merck Sharp & Dohme Corp. | Alkyne benzotriazole derivatives |
| EP2650284A1 (en) * | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Heterocyclic derivatives as metabotropic glutamate receptor modulators |
| MX358311B (en) | 2012-04-17 | 2018-08-14 | Fujifilm Corp | HETEROCICLIC COMPOUND CONTAINING NITROGEN OR SALT OF THE SAME. |
| EP3191441B1 (en) | 2014-09-09 | 2020-02-19 | Boehringer Ingelheim International Trading (Shanghai) Co. Ltd. | Novel process for preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione |
| JP2021524850A (en) * | 2018-05-17 | 2021-09-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Tricyclic sulfone compound as a RORγ regulator |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES413944A1 (en) | 1972-04-20 | 1976-06-01 | Merz & Co | Drugs or medicines for influencing the central nervous system |
| DE2856393C2 (en) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Medicines used to treat Parkinson's disease |
| EP0392059B1 (en) | 1989-04-14 | 1993-09-15 | Merz & Co. GmbH & Co. | Use of adamantane derivatives in the prevention and treatment of cerebral ischemia |
| AU2002249275A1 (en) | 2002-03-08 | 2003-09-22 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
| CA2497658A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| JP2006504665A (en) | 2002-08-13 | 2006-02-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| WO2007023242A1 (en) | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| US20080045521A1 (en) | 2006-06-09 | 2008-02-21 | Astrazeneca Ab | Phenylalanine derivatives |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
-
2011
- 2011-10-18 WO PCT/EP2011/068205 patent/WO2012052451A1/en not_active Ceased
- 2011-10-18 AR ARP110103856A patent/AR083475A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012052451A1 (en) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077796A1 (en) | METABOTROPIC GLUTAMATE RECEIVERS MODULATORS | |
| AR083475A1 (en) | METABOTROPIC GLUTAMATE RECEIVERS MODULATORS | |
| AR076435A1 (en) | COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES | |
| AR052902A1 (en) | DERIVATIVES OF PIRIDAZINE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE AS THERAPEUTIC AGENTS FOR DISEASES MEDIATED BY ESTEAROIL-COA DESATURASA | |
| AR068846A1 (en) | COMPOUNDS DERIVED FROM PIRROLO (2,3D) -PIRIMIDINE INHIBITORS OF PKB ACTIVITY, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESS AND USE OF THE SAME AS ANTICANCER AGENTS | |
| CR20160548A (en) | New Pirazolo Pyrimidine Derivatives and their Use as MALT1 Inhibitors | |
| AR055592A1 (en) | DERIVATIVES OF 2-AMINO-5-CYCLALKYL-HYDANTOINE AS MODULATORS AND / OR INHIBITORS OF BETA-SECRETASE (BACE) | |
| ES2659397T3 (en) | 2-substituted azabicyclics and their use as orexin receptor modulators | |
| PE20170682A1 (en) | PYRIMIDINE DERIVATIVES SUBSTITUTED WITH OPTIONALLY CONDENSED HETERO CYCLYL USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES | |
| AR085316A1 (en) | PIRROLO DERIVATIVES [2,3-B] PIRIDINE, USEFUL FOR THE MODULATION OF KINASES | |
| AR067646A1 (en) | ARILOXAZOLES REPLACED AND ITS USE | |
| AR100810A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
| AR100806A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
| AR123848A1 (en) | SPIRO HETEROCYCLIC COMPOUNDS AND METHODS OF USE | |
| PE20161368A1 (en) | DIACILGLICEROL ACILTRANFERASE 2 INHIBITORS | |
| AR110282A1 (en) | BICYCLIC AMIDA COMPOUNDS AND USE OF THESE IN THE TREATMENT OF DISEASES MEDIATED BY RIP1 | |
| AR084515A1 (en) | NITROGEN HETEROCICLICAL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF DISEASES ASSOCIATED WITH THE CENTRAL NERVOUS SYSTEM SUCH AS PARKINSON AND ALZHEIMER, BETWEEN OTHER | |
| AR086036A1 (en) | ETHYLLY DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF (mGluR5) | |
| AR076401A1 (en) | BISARIL ALQUINILAMIDAS AS NEGATIVE ALLOSTERIC MODULATORS OF THE METABOTROPIC RECEIVER OF GLUTAMATE 5 (MGLUR5) | |
| PE20181853A1 (en) | 1,5-DIHYDRO-4H-PYRAZOLE [3,4-D] PYRIMIDIN-4-ONAS AND 1,5-DIHYDRO-4H-PIRAZOLO [4,3-C] PYRIDIN-4-ONAS AS PDE1 INHIBITORS | |
| AR071512A1 (en) | IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF 11B-HSD1 | |
| PE20161369A1 (en) | DIHYDROPYRIDINONE MONOACILGLYCEROL INHIBITORS 2 (MGAT2) SUBSTITUTE WITH TETRAZOLONE | |
| PE20190106A1 (en) | ZESTE APPROVAL ENHANCER INHIBITORS 2 | |
| AR067648A1 (en) | DERIVATIVES OF 2-AZA-BICYCLE [2,2,2] OCTOBER, USE OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR046793A1 (en) | DERIVADOS DE PIRAZOL, ANTAGONISTS OF THE RECEIVER OF OREXINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |